TY - JOUR
TI - Application of paclitaxel-eluting metal mesh stents within the pig
ureter: An experimental study
AU - Liatsikos, Evangelos N.
AU - Karnabatidis, Dimitrios
AU - Kagadis, George
AU - C.
AU - Rokkas, Kostantinos
AU - Constantinides, Costas
AU - Christeas,
AU - Nikolaos
AU - Flaris, Nikolaos
AU - Voudoukis, Theodore
AU - Scopa,
AU - Chrisoula D.
AU - Perimenis, Petros
AU - Filos, Kriton S.
AU - Nikiforidis,
AU - George C.
AU - Stolzenburg, Jens-Uwe
AU - Siablis, Dimitrios
JO - European urology oncology
PY - 2007
VL - 51
TODO - 1
SP - 217-223
PB - ELSEVIER SCIENCE BV
SN - null
TODO - 10.1016/j.eururo.2006.05.054
TODO - ureter; hyperplasia; paclitaxel; metal stents
TODO - Objective: The purpose of the present study is to compare the standard
bare metal stents (BMS) with the Paclitaxel-Drug Eluting Stent (DES) in
the ureter of a pig model.
Materials and methods: We report on an experimental study with ten
female pigs weighing between 25 and 30 kg. The stents were randomly
placed in either the right or left ureter in each of 10 study animals,
for a total of 20 stented ureters. Ten ureters were stented with an
R-Stent (Orbus Medical Technologies, Hoevelaken Netherlands), and ten
with a Paclitaxel-Eluting Coronary Stent (Boston Scientific, Natick, MA,
USA). Patency was measured by radiograph of the nephrostomy tract,
intravenous urography and virtual endoscopy at 24 hours and 21 days
after the initial procedure, respectively.
Results: Free flow of urine through the stents into the bladder was
documented in all stented ureters 24 hours after stent insertion by
radiograph of the nephrostomy tract. At the 21 day follow-up
examination, 5 R-Stents were found to be completely occluded and two
partially stenosed, whereas no occluded stent was detected in the
Paclitaxel-DES group. Pathology examination of the stents at 21 days
follow-up showed that the obstructed R-Stents generated severe
inflammation with metaplasia of the urothelium. The Paclitaxel-Eluting
MS generated a mild inflammatory response within the ureteral lumen at
the site of the stent, without hindering ureteral patency. R-stents
proved to develop more hyperplasia compared to the Paclitaxel-Eluting
MS.
Conclusions: Paclitaxel-DES, when compared with the standard R-Stent
BMS, generated less inflammation and/or hyperplasia of the surrounding
tissues, thus maintaining ureteral patency. Long-term animal trials are
required to further validate our results. (c) 2006 European Association
of Urology. Published by Elsevier B.V. All rights reserved.
ER -